Validation of a Molecular and Pathological Model for Five-Year Mortality Risk in Patients with Early Stage Lung Adenocarcinoma
Open Access
- 1 January 2015
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 10 (1) , 67-73
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Results of Initial Low-Dose Computed Tomographic Screening for Lung CancerNew England Journal of Medicine, 2013
- A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studiesThe Lancet, 2012
- A Five-Gene and Corresponding Protein Signature for Stage-I Lung Adenocarcinoma PrognosisClinical Cancer Research, 2011
- Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2010
- Gene Expression-Based Prognostic Signatures in Lung Cancer: Ready for Clinical Use?JNCI: Journal of the National Cancer Institute, 2010
- CALGB 9633: An Underpowered Trial With a Methodologically Questionable ConclusionJournal of Clinical Oncology, 2009
- Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study GroupsJournal of Clinical Oncology, 2008
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative GroupJournal of Clinical Oncology, 2008
- Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation studyNature Medicine, 2008
- Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non–Small-Cell Lung Cancer GuidelineJournal of Clinical Oncology, 2007